Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates
2018603 citationsStaci Sabnis, E. Sathyajith Kumarasinghe et al.Molecular Therapyprofile →
Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses
2017493 citationsKapil Bahl, Olga Yuzhakov et al.Molecular Therapyprofile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
This map shows the geographic impact of Alex Bulychev's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alex Bulychev with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alex Bulychev more than expected).
This network shows the impact of papers produced by Alex Bulychev. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alex Bulychev. The network helps show where Alex Bulychev may publish in the future.
Co-authorship network of co-authors of Alex Bulychev
This figure shows the co-authorship network connecting the top 25 collaborators of Alex Bulychev.
A scholar is included among the top collaborators of Alex Bulychev based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Alex Bulychev. Alex Bulychev is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
All Works
7 of 7 papers shown
1.
Sabnis, Staci, E. Sathyajith Kumarasinghe, Timothy Salerno, et al.. (2018). A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates. Molecular Therapy. 26(6). 1509–1519.603 indexed citations breakdown →
2.
Bahl, Kapil, Olga Yuzhakov, Alex Bulychev, et al.. (2017). Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses. Molecular Therapy. 25(6). 1316–1327.493 indexed citations breakdown →
Li, Yu, Alex Bulychev, Lisa M. O’Brien, et al.. (2009). Abstract #2921: Pharmacokinetics and pharmacodynamics of a selective proteasome inhibitor MLN9708 in nonclinical species following either intravenous or oral administration. Cancer Research. 69. 2921–2921.4 indexed citations
Bulychev, Alex, et al.. (2003). [Effect of immunosuppressors cyclophosphane and 5-fluorouracil on natural cytotoxicity and activity of lysosomal enzymes of splenocytes in C3HA mice].. PubMed. 45(1). 74–80.1 indexed citations
7.
Bulychev, Alex, et al.. (1986). [Effect of the segregation of neutral red, acridine orange and ammonium chloride by L cells (subline LSM) on lysosomal hydrolase activity].. PubMed. 28(7). 703–12.1 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.